Abstract
A series of pyrrolidine based inhibitors of dipeptidyl peptidase IV were developed from a high throughput screening hit for the treatment of type 2 diabetes. Potency, selectivity, and pharmacokinetic properties were optimized resulting in the identification of a pre-clinical candidate for further profiling.
MeSH terms
-
Animals
-
Crystallography, X-Ray
-
Dipeptidyl Peptidase 4 / chemistry
-
Dipeptidyl Peptidase 4 / metabolism*
-
Dipeptidyl-Peptidase IV Inhibitors*
-
Dogs
-
Fluorine / chemistry*
-
Humans
-
Models, Molecular
-
Molecular Structure
-
Protease Inhibitors / chemical synthesis
-
Protease Inhibitors / chemistry*
-
Protease Inhibitors / pharmacokinetics
-
Protease Inhibitors / pharmacology*
-
Pyrrolidines / chemical synthesis
-
Pyrrolidines / chemistry*
-
Pyrrolidines / pharmacokinetics
-
Pyrrolidines / pharmacology*
-
Rats
-
Stereoisomerism
Substances
-
Dipeptidyl-Peptidase IV Inhibitors
-
Protease Inhibitors
-
Pyrrolidines
-
Fluorine
-
Dipeptidyl Peptidase 4
-
pyrrolidine